UK Markets close in 11 mins

Athenex, Inc. (ATNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.4180+0.0086 (+2.10%)
As of 11:15AM EDT. Market open.
Sign in to post a message.
  • R
    Do you guys follow ( It seems way better than all the spam on the ATNX board - The alerts have been great!
  • M
    All directors except CEO filed form 4
  • J
    Anyone catch the Truist event? According to the news release last week there was supposed to be a link to the webcast on Athenex's website up for 90 days. If they're just reiterating the PDF of slides up on the Athenex site, for June 2022, it doesn't look all that interesting or exciting.

    Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Daniel Lang, M.D., President, Athenex Cell Therapy, will participate in The Next Cells & Mechanisms to Watch in Oncology panel at the Truist Securities Cell Therapy Symposium on Tuesday, June 28, 2022 at 11:30 am Eastern Time in New York, NY. Company management will also participate in one-on-one investor meetings during the event.

    Registration is available on the Truist symposia-cel website. An audio archive of the webcast will be available in the "Events and Presentations" section of the Athenex website for the following 90 days.
  • E
    Er. Pradip Chitrakar
    getting closer to zero.
  • J
    ATNX only has around 80 trading days left to log a minimum closing price of > $1 for 10 consecutive days right? So they are actually down to 70 trading days, as it has end up above $1 on consecutive days.

    Three more weeks until the annual meeting.

    Not sure why the 2 directors serving since June 2015, and April 2019 deserve to be reelected for another 3 years, after sitting through the Priority Review, and CRL debacle.

    Not sure why anyone would want to vote for compensation packages for the NEOs. What has leadership accomplished? Where are the revenues? Why is my (and others) investment down 80% or more? When will profitability come?

    "Our stockholders will have an opportunity to cast an advisory vote on the compensation for our NEOs at the Annual Meeting. Our Board has recommended, subject to their further consideration of the preference of our stockholders (as reflected in the non-binding advisory vote on say-on-pay at the Annual Meeting and the frequency of future say-on-pay votes), that stockholders be provided an annual advisory vote on the compensation of our NEOs."
  • G
    We need a 50 million dollar investment…
  • s
    i have a hard time understand they sell something 85million when the stock is worth 60 ... something to think about
  • L
    Lash LaRue
    It might be too late, but board should be considering bringing in a "Turnaround CEO" or interim CEO to bring this back. Some items the turnaround team can initiate immediately:
    - Assess and restructure asset acquisition deals, deep review of agreements and contracts
    - ID capabilities that are under-utilized
    - Look at cash sinks - IT, high payrolls, balloon or instalment payments for acquisitions
    - Identify key employees to champion turnaround
    - Get advisors with turnaround expertise in Pharma
    - Transition leadership from bureaucrats to nimble entrepreneurial “lean” team (or replace)
    - Retool KPIs to a improve margins
    - Long-time employees need to feel career risk to push innovation and productivity
    - Realistic forecasting
    - Identify and cease non-critical spending
    - Renegotiate debt and notes
    - Save costs by reviewing and renegotiation or replacing current support contracts (e.g. legal, IT, accounting, etc.)
    - Identify management positions that can be consolidated
  • t
  • M
    NCT04013217 will complete 7/31, do we expect anything from this? I know it is phase 1
  • Y
    Yahoo Finance Insights
    Athenex reached an all time low at 0.45
  • C
    Question: what’s the value of their pharmacy business? Every quarter it’s the only thing that’s really selling anything.
    Just that one component. Is it .60; .80; $2 / share?
  • C
    yes fairly good news alright....I've been adding today on the general market weakness
  • C
    Well, the value of the pharmacy business is $6mil after costs. It’s the only thing generating revenue. That’s a nickel per share. Maybe when the sp drops to a nickel I’ll average down.
  • C
    Source: GlobeNewswire Inc.

    Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its Marketing Authorization Application (MAA) for oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of advanced breast cancer has been validated by the United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA) for review . The application qualifies for a 150 day assessment by which a decision on approvability of the product will be provided.


  • J
    Helping kids fight cancer sounds pretty darn good to me!
  • J
  • C
    quite unreal how this drops daily....doesn't even matter is markets up or down
  • S
    Athenex Leadership needs to take responsibility for this and take salary cuts and buy stocks! Unbelievable what is happening!